ASX:LSH

Lifespot Health Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume120,633 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Lifespot Health (ASX:LSH) Vs. BUX, IME, BD1, CRL, CTE, and DVL

Should you be buying LSH stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Lifespot Health, including (BUX) (BUX), 12144 (IME), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), and dorsaVi (DVL).

Lifespot Health (ASX:LSH) and (BUX) (CNSX:BUX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Lifespot Health and (BUX)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifespot Health$22,127.000.00$-2,021,604.10A($0.01)N/A
(BUX)N/AN/AN/AN/AN/A

(BUX) has lower revenue, but higher earnings than Lifespot Health.

Profitability

This table compares Lifespot Health and (BUX)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lifespot HealthN/AN/AN/A
(BUX)N/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Lifespot Health and (BUX), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lifespot Health0000N/A
(BUX)0000N/A

Summary

Lifespot Health beats (BUX) on 1 of the 1 factors compared between the two stocks.

Lifespot Health (ASX:LSH) and 12144 (CNSX:IME) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Lifespot Health and 12144's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifespot Health$22,127.000.00C$-2,021,604.10A($0.01)N/A
12144N/AN/AN/AN/AN/A

12144 has lower revenue, but higher earnings than Lifespot Health.

Profitability

This table compares Lifespot Health and 12144's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lifespot HealthN/AN/AN/A
12144N/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Lifespot Health and 12144, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lifespot Health0000N/A
121440000N/A

Summary

Lifespot Health beats 12144 on 1 of the 1 factors compared between the two stocks.

Lifespot Health (ASX:LSH) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Lifespot Health and BARD1 Life Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifespot Health$22,127.000.00$-2,021,604.10A($0.01)N/A
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A

Lifespot Health has higher earnings, but lower revenue than BARD1 Life Sciences.

Profitability

This table compares Lifespot Health and BARD1 Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lifespot HealthN/AN/AN/A
BARD1 Life SciencesN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Lifespot Health and BARD1 Life Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lifespot Health0000N/A
BARD1 Life Sciences0000N/A

Summary

Lifespot Health beats BARD1 Life Sciences on 2 of the 3 factors compared between the two stocks.

Charles River Laboratories International (CNSX:CRL) and Lifespot Health (ASX:LSH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Charles River Laboratories International and Lifespot Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International0000N/A
Lifespot Health0000N/A

Valuation & Earnings

This table compares Charles River Laboratories International and Lifespot Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories InternationalN/AN/AN/AN/AN/A
Lifespot Health$22,127.000.00$-2,021,604.10A($0.01)N/A

Charles River Laboratories International has higher earnings, but lower revenue than Lifespot Health.

Profitability

This table compares Charles River Laboratories International and Lifespot Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories InternationalN/AN/AN/A
Lifespot HealthN/AN/AN/A

Summary

Lifespot Health beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

Cryosite (ASX:CTE) and Lifespot Health (ASX:LSH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Earnings & Valuation

This table compares Cryosite and Lifespot Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryosite$9.71 million0.00$515,455.60A$0.01N/A
Lifespot Health$22,127.000.00$-2,021,604.10A($0.01)N/A

Cryosite has higher revenue and earnings than Lifespot Health.

Profitability

This table compares Cryosite and Lifespot Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CryositeN/AN/AN/A
Lifespot HealthN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cryosite and Lifespot Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryosite0000N/A
Lifespot Health0000N/A

Summary

Cryosite beats Lifespot Health on 3 of the 3 factors compared between the two stocks.

dorsaVi (ASX:DVL) and Lifespot Health (ASX:LSH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for dorsaVi and Lifespot Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
dorsaVi0000N/A
Lifespot Health0000N/A

Earnings & Valuation

This table compares dorsaVi and Lifespot Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A
Lifespot Health$22,127.000.00$-2,021,604.10A($0.01)N/A

Lifespot Health has lower revenue, but higher earnings than dorsaVi.

Profitability

This table compares dorsaVi and Lifespot Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
dorsaViN/AN/AN/A
Lifespot HealthN/AN/AN/A

Summary

dorsaVi beats Lifespot Health on 2 of the 3 factors compared between the two stocks.


Lifespot Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
BD1
BARD1 Life Sciences
0.5N/AN/A$0.00$612,251.000.00High Trading Volume
Gap Up
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
CTE
Cryosite
0.6N/AN/A$0.00$9.71 million0.00High Trading Volume
Gap Up
DVL
dorsaVi
0.5N/AN/A$0.00$1.65 million0.00High Trading Volume
Gap Up
Epigenomics logo
EPGNY
Epigenomics
0.6$13.77flat$0.00N/A0.00
ETAH
Eternity Healthcare
0.6$0.00flat$0.00N/A0.00Gap Up
GSS
Genetic Signatures
0.0N/AN/A$0.00$29.13 million0.00High Trading Volume
GTG
Genetic Technologies
0.0N/AN/A$0.00$25,714.000.00High Trading Volume
IBX
Imagion Biosystems
0.6N/AN/A$0.00$2.70 million0.00High Trading Volume
Gap Up
IDX
Integral Diagnostics
0.8N/AN/A$0.00$314.82 million0.00High Trading Volume
Gap Up
MEDD
Medical Imaging
0.4$0.01flat$0.00N/A0.00Gap Down
OSL
OncoSil Medical
0.5N/AN/A$0.00$2.22 million0.00High Trading Volume
Gap Up
PRLX
Parallax Health Sciences
0.5$0.02flat$0.00N/A0.00Gap Up
RHY
Rhythm Biosciences
0.0N/AN/A$0.00$1.21 million0.00High Trading Volume
Sartorius Aktiengesellschaft logo
SRT3
Sartorius Aktiengesellschaft
0.6$459.00flat$0.00N/A0.00High Trading Volume
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.5$28.08flat$0.00N/A0.00
SIL
Smiles Inclusive
0.4N/AN/A$0.00$36.48 million0.00High Trading Volume
Gap Up
VHT
Volpara Health Technologies
0.5N/AN/A$0.00$15.22 million0.00High Trading Volume
Gap Up
OBJ
Wellfully Limited (OBJ.AX)
0.0N/AN/A$0.00$1.48 million0.00High Trading Volume
WUXIF
WuXi AppTec
1.0$18.50flat$0.00N/A0.00Gap Down
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.